Advertisement

Topics

Latest "Placebo Hepatitis Virus Infection" News Stories

20:53 EDT 22nd August 2017 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 7,000+

Extremely Relevant

An update on the management of chronic hepatitis B and C infection

Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-a...


Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.

Researchers identify how class of drugs blocks Hepatitis C virus replication

Globally, an estimated 71 million people are living with chronic hepatitis C virus (HCV). Over decades of infection, chronic HCV infection results in progressive damage to the liver and an increased risk for end stage liver disease and liver cancer, making the virus the leading cause of liver-related deaths in the United States today.


[Correspondence] New hepatitis C antiviral treatments eliminate the virus

The Cochrane Collaboration has published a topical systematic review1 and meta-analysis on direct-acting antivirals (DAA) for chronic hepatitis C virus (HCV) infection. Jakobsen and colleagues1 compared the results of randomised trials of any HCV DAA regimen versus no intervention or placebo. Their review reported data from 138 trials, which included 25 232 participants and encompassed all drugs...

Statins may benefit cirrhotic patients with Hepatitis B or C infections

(Wiley) Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related cirrhosis.

New hepatitis data highlight need for urgent global response

New WHO data reveal that an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The WHO Global hepatitis report, 2017 indicates that the large majority of these people lack access to life-saving testing and treatment. As a result, millions of people are at risk of a slow progression to chronic liver disease, cancer, and deat...

Outbreak of Hepatitis A linked to bakery as nine people hospitalised with liver infection – Mirror.co.uk

Mirror.co.ukOutbreak of Hepatitis A linked to bakery as nine people hospitalised with liver infectionMirror.co.ukAn outbreak of Hepatitis A could be linked to a bakery after nine confirmed cases and nine suspected cases have led investigators to the shop. Hepatitis A is a liver infection caused by a virus that is spread in the poo of an infected person, and is ...Nine people hospitalised with hepa...

No Consistent Pattern of HBV Reactivation With Direct-acting Antivirals for HCV

The largest case review to date of hepatitis B virus (HBV) reactivation associated with direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection found no consistent pattern in terms of which patients are likely to develop this adverse event. Reuters Health Information

Global Hepatitis Drug Market & Clinical Trials Insight 2023

LONDON, June 28, 2017 /PRNewswire/ -- "Global Hepatitis Drug Market & Clinical Trials Insight 2023" report gives comprehensive insight on various clinical and non-clinical advancements in the global Hepatitis drug market. Currently, there are 321 Hepatitis drugs in clinical pipeline and 110 Hepatitis drugs are commercially available in the market. Hepatitis drug clinical trials landscape is do...

Statins may provide favorable outcomes to patients with HBV- or HCV-related cirrhosis

Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related cirrhosis.

Statins may provide favorable effects in patients with HBV- or HCV-related cirrhosis

Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related cirrhosis.

New interferon shows promise against hepatitis B in cell culture, and animal model

Hepatitis B is notoriously difficult to eradicate with currently available agents.. Now, in a new study, a novel form of "pegylated" interferon-β has reduced hepatitis B virus (HBV) infections in experimental human-derived cells and in mice more effectively than the conventional pegylated interferon-α2a, suggesting that it could lead to improved treatment for hepatitis B infection in humans. The...

Report: Hepatitis C Rates on the Rise Among Reproductive-aged Women

The incidence of hepatitis C virus infection has increased among young people who inject drugs, about half of whom are women of reproductive age, according to the CDC.

Scientists step closer to drug treatment for hepatitis B

A major new insight into how Hepatitis B Virus works could pave the way for new drug treatments for the infection which is the major cause of liver cancer worldwide.

Hepatitis C treatment: Genes found that calibrate how our immune system affects virus

ECDC report: Ten-fold increase of hepatitis E cases in the EU/EEA between 2005 and 2015

The incidence of hepatitis E virus (HEV) infection has been steadily increasing across the countries of the European Union and European Economic Area (EU/EEA) with 21 081 cases reported in the EU/EEA over the last decade.

[Articles] Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study

Semen alterations early after acute Zika virus infection might affect fertility and could be explained by virus effects on the testis and epididymis. Frequency of shedding and high viral load in semen, together with the presence of replicative virus in a motile spermatozoa fraction, can lead to Zika virus transmission during sexual contact and assisted reproduction procedures. Whole blood seems to...

Nine in 10 people unaware they have hepatitis

The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with an emphasis that much work is left to be done to combat the viral infection. The organisation called for national responses towards hepatitis elimination to be accelerated and suggested that, at best, only one in 10 people were aware that they had the illness. In further cause of con...

New EASL clinical practice guidelines on the management of hepatitis B virus

The European Association for the Study of the Liver (EASL) today published their revised Clinical Practice Guidelines (CPGs) on the management of Hepatitis B virus (HBV) infection. The CPGs, which will also be presented in a session at The International Liver Congress 2017 in Amsterdam, The Netherlands, are designed to help physicians and healthcare providers optimise the management of patients wi...

Scientists a step closer to drug treatment for hepatitis B

A major new insight into how hepatitis B virus works could pave the way for new drug treatments for the infection which is the major cause of liver cancer worldwide, report scientists.

AbbVie’s Maviret approved in Europe for chronic hepatitis C

AbbVie’s maviret (glecaprevir/pibrentasvir) has secured the approval of the European Commission for the treatment of chronic hepatitis C virus (HCV) infection in all major genotypes from GT1 to GT6 in adult patients.

Lion TCR Pte Ltd. Release: Breakthrough Immunotherapy For Chronic Hepatitis B Virus Infection

  Life Sciences Jobs   ...

Lion TCR Release: Breakthrough Immunotherapy For Chronic Hepatitis B Virus Infection

  Life Sciences Jobs   ...

Point-of-care hep C test developed

A research team led by UNSW’s Kirby Institute has evaluated a new test that enables diagnosis of hepatitis C infection in a single visit, with promising results. Their study has been published in The Lancet Gastroenterology & Hepatology. The researchers conducted the first evaluation of the Xpert HCV Viral Load test, manufactured by molecular diagnostics company Cepheid — a point-of-care ...

Around 9 million Europeans are affected by chronic hepatitis B or C

An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection. However, large numbers of them are not even aware of their infection as they have not yet been tested and diagnosed. On the occasion of World Hepatitis Day on 28 July, ECDC Director Andrea Ammon highlights the need for Europe to scale-up coverage of testing, prevent...


Quick Search
Advertisement
 

News Quicklinks